Form 4: Supernus Director Sells 5,369 Shares Under 10b5-1 Plan

Supernus Pharmaceuticals Director Frederick M. Hudson sold 5,369 shares of common stock at a weighted average price of $50.61 per share under a pre-arranged trading plan.

Summary

• Director Frederick M. Hudson of Supernus Pharmaceuticals, Inc. (SUPN) sold 5,369 shares of common stock.
• The transaction occurred on March 12, 2026.
• The shares were sold at a weighted average price of $50.61, with individual transaction prices ranging from $50.45 to $50.82.
• Following this transaction, Mr. Hudson directly beneficially owns 60,413 shares of Supernus common stock.
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan, indicating it was pre-scheduled.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale by a director, while reducing insider ownership, was conducted under a Rule 10b5-1 plan, suggesting it was a pre-scheduled personal financial management decision rather than a reaction to new company-specific information.

Negatives

• An insider sale, even if pre-planned, reduces management's direct equity stake in the company, which some investors may interpret as a slight reduction in confidence.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, even when conducted under a Rule 10b5-1 plan, are routinely monitored by investors for potential signals regarding management's confidence in the company's future prospects. While a 10b5-1 plan suggests the sale was pre-scheduled and not based on immediate material non-public information, the market still observes the overall trend of insider holdings.

Stakeholder Impact

• Shareholders: May interpret the sale as a slight reduction in insider confidence, though the execution under a 10b5-1 plan mitigates this concern by indicating a pre-planned transaction.

Key Dates

Recommendation

The filing reports a routine insider sale by a director under a pre-established 10b5-1 plan. This type of transaction is generally not indicative of a change in the company's fundamental prospects and does not warrant a change in investment recommendation based solely on this filing. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

Supernus Pharmaceuticals, SUPN, Insider Sale, Form 4, Director Transaction, Stock Sale, Frederick M. Hudson, Rule 10b5-1